FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385514> ?p ?o ?g. }

• W4308385514 abstract "<h3>Background</h3> Lung cancer has higher incidence and mortality in the elderly population, although substantial evidence confirms the efficacy of PD-1/L1 inhibitors in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) regardless of PD-L1 expression. However, efficacy and safety of immunotherapy in elderly NSCLC remains unclear, with most evidence is sourced from subgroup analysis of prospective clinical trials.¹ Elderly lung cancer patients often have more underlying diseases and function of major organs decreases with ageing,² safety is certainly a key factor that must be carefully considered when these patients receive treatment because of poor tolerability. Therefore, we designed the study of tislelizumab in combination with pemetrexed and bevacizumab for the treatment of elderly non-squamous NSCLC. To improve safety and tolerability, we remove the more toxic platinum from the chemotherapy regimen, and the anti-angiogenic agent bevacizumab, with relatively mild adverse effect, was added to avoid decreased efficacy. This study aims to explore the efficacy and safety of this treatment regimen in elderly NSCLC patients. <h3>Methods</h3> This open-label, single arm, phase I clinical study is enrolling patients aged≥65 years with histologically or cytologically confirmed, untreated IIIB/IIIC/IV(according to AJCC 8th) non-squamous NSCLC. Patients must have measurable disease per RECIST v1.1; ECOG PS of 0 or 1; without harboring EGFR-sensitizing mutation or ALK and ROS1 gene translocation; no active autoimmune disease, bleeding risk, or coagulation disorders. Patients will receive 4 cycles of pemetrexed (500mg/m², d1) Q3W and tislelizumab (200mg, d4) Q3W in combination with bevacizumab (7.5mg/kg, d1) Q3W followed by tislelizumab (200mg, d1) Q3W and bevacizumab (7.5mg/kg, d1) Q3W, until disease progression, unacceptable AEs, investigator/patient decision or 2 years. The primary endpoint is objective response rate (ORR) by RECIST v1.1. Secondary endpoints include overall survival (OS), progress-free survival (PFS), duration of response (DOR), health-related quality of life (HRQoL) and safety. HRQoL is assessed using EORTC QLQ-C30 questionnaires; AEs are graded according to NCI CTCAE v5.0. This study will enroll 30 patients and enrollment is ongoing. <h3>Trial Registration</h3> ClinicalTrials. gov NCT05273814 <h3>References</h3> Fang Yang, Svetomir NM, Julian RM, <i>et al</i>. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status with Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Netw Open.</i> 2020;<b>3</b>:e2012534. Vera C, Direndra H, Encarnação T, <i>et al</i>. Characterization and management of elderly and very elderly patients with non-small cell lung cancer. <i>Clin Respir J</i> 2020;<b>14</b>:683–686. <h3>Ethics Approval</h3> The study was approved by Tianjin Medical University Cancer Institute & Hospital Ethics Board, approval number E20210962A." @default.
• W4308385514 created "2022-11-11" @default.
• W4308385514 creator A5003554962 @default.
• W4308385514 creator A5074216961 @default.
• W4308385514 date "2022-11-01" @default.
• W4308385514 modified "2023-10-16" @default.
• W4308385514 title "704 Phase I study of tislelizumab in combination with bevacizumab and pemetrexed in first-line treatment for advanced elderly non-squamous non-small cell lung cancer: trial in progress" @default.
• W4308385514 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0704" @default.
• W4308385514 hasPublicationYear "2022" @default.
• W4308385514 type Work @default.
• W4308385514 citedByCount "0" @default.
• W4308385514 crossrefType "proceedings-article" @default.
• W4308385514 hasAuthorship W4308385514A5003554962 @default.
• W4308385514 hasAuthorship W4308385514A5074216961 @default.
• W4308385514 hasBestOaLocation W43083855141 @default.
• W4308385514 hasConcept C121608353 @default.
• W4308385514 hasConcept C126322002 @default.
• W4308385514 hasConcept C143998085 @default.
• W4308385514 hasConcept C197934379 @default.
• W4308385514 hasConcept C2776256026 @default.
• W4308385514 hasConcept C2776694085 @default.
• W4308385514 hasConcept C2776907518 @default.
• W4308385514 hasConcept C2777240266 @default.
• W4308385514 hasConcept C2777802072 @default.
• W4308385514 hasConcept C2778239845 @default.
• W4308385514 hasConcept C2778375690 @default.
• W4308385514 hasConcept C2779984678 @default.
• W4308385514 hasConcept C2781413609 @default.
• W4308385514 hasConcept C2908647359 @default.
• W4308385514 hasConcept C31760486 @default.
• W4308385514 hasConcept C535046627 @default.
• W4308385514 hasConcept C71924100 @default.
• W4308385514 hasConcept C99454951 @default.
• W4308385514 hasConceptScore W4308385514C121608353 @default.
• W4308385514 hasConceptScore W4308385514C126322002 @default.
• W4308385514 hasConceptScore W4308385514C143998085 @default.
• W4308385514 hasConceptScore W4308385514C197934379 @default.
• W4308385514 hasConceptScore W4308385514C2776256026 @default.
• W4308385514 hasConceptScore W4308385514C2776694085 @default.
• W4308385514 hasConceptScore W4308385514C2776907518 @default.
• W4308385514 hasConceptScore W4308385514C2777240266 @default.
• W4308385514 hasConceptScore W4308385514C2777802072 @default.
• W4308385514 hasConceptScore W4308385514C2778239845 @default.
• W4308385514 hasConceptScore W4308385514C2778375690 @default.
• W4308385514 hasConceptScore W4308385514C2779984678 @default.
• W4308385514 hasConceptScore W4308385514C2781413609 @default.
• W4308385514 hasConceptScore W4308385514C2908647359 @default.
• W4308385514 hasConceptScore W4308385514C31760486 @default.
• W4308385514 hasConceptScore W4308385514C535046627 @default.
• W4308385514 hasConceptScore W4308385514C71924100 @default.
• W4308385514 hasConceptScore W4308385514C99454951 @default.
• W4308385514 hasLocation W43083855141 @default.
• W4308385514 hasOpenAccess W4308385514 @default.
• W4308385514 hasPrimaryLocation W43083855141 @default.
• W4308385514 hasRelatedWork W2085889668 @default.
• W4308385514 hasRelatedWork W2092151800 @default.
• W4308385514 hasRelatedWork W2103442078 @default.
• W4308385514 hasRelatedWork W2358450743 @default.
• W4308385514 hasRelatedWork W2604148568 @default.
• W4308385514 hasRelatedWork W3011176692 @default.
• W4308385514 hasRelatedWork W3029430426 @default.
• W4308385514 hasRelatedWork W3209656967 @default.
• W4308385514 hasRelatedWork W4256013750 @default.
• W4308385514 hasRelatedWork W49755809 @default.
• W4308385514 isParatext "false" @default.
• W4308385514 isRetracted "false" @default.
• W4308385514 workType "article" @default.